Stocks›Basic Materials›NAMS

NAMS

Name: AlgoThesis
Author: algothesis

NewAmsterdam Pharma Company N.V.

NasdaqResearch view

Basic Materials · Pharmaceutical Preparations · SEC EDGAR FY 2025-12-31

Price history

Interactive · live data via TradingView

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2025-12-31

Revenue$22.5M

Net Income$-203.8M

Gross Profit—

Oper Income$-225.7M

EPS (dil)$-1.72

Rev/sh$0.19

FCF/sh—

Book/sh$5.85

Cash/sh$4.19

40+ fundamentals from SEC EDGAR (public domain) — deeper than a typical screener's ratio table.

Revenue & Earnings — fiscal year

$102.7M

2022

$14.1M

2023

$45.6M

2024

$22.5M

2025

Financials — annual

SEC EDGAR · last 4 FY

USD	FY2022	FY2023	FY2024	FY2025
Revenue	$102.7M	$14.1M	$45.6M	$22.5M
Gross Profit	—	—	—	—
Operating Income	$-3.6M	$-183.0M	$-176.3M	$-225.7M
Net Income	$-22.6M	$-176.9M	$-241.6M

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

COMMUNITY · $NAMS0 theses

POST YOUR TAKE →

Related Stocks

Loading peers…

Ask AI about NAMS Build basket with NAMS Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.

NAMS NewAmsterdam Pharma Company N.V. Stock — fundamentals, financials & AI research · AlgoThesis